Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 4/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 1/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | STAT6 | P42226 | 1/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | PAX8 | Q06710 | 3/20 | 0.81 |
| ▸ | SLC29A1 | Q99808 | 4/20 | 0.76 |
| ▸ | TP53 | P04637 | 3/20 | 0.76 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | MITF | O75030 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metrifudil SCHEMBL29392205 | 1.00 | ADORA3 (1.00) | ADORA3ADORA2AADORA1TSHRNFKB1 | |
| Metrifudil SCHEMBL2778420 | 1.00 | ADORA3 (1.00) | ADORA3ADORA2AADORA1TSHRNFKB1 | |
| Metrifudil SCHEMBL638410 | 1.00 | ADORA3 (1.00) | ADORA3ADORA2AADORA1TSHRNFKB1 | |
| SCHEMBL640252 | 0.93 | ADORA3 (0.86) | ADORA3ADORA2AADORA1TSHRNFKB1 | |
| SCHEMBL640251 | 0.93 | ADORA3 (0.86) | ADORA3ADORA2AADORA1TSHRNFKB1 | |
| SCHEMBL639812 | 0.93 | ADORA3 (0.86) | ADORA3ADORA2AADORA1TSHRNFKB1 | |
| SCHEMBL639811 | 0.93 | ADORA3 (0.86) | ADORA3ADORA2AADORA1TSHRNFKB1 | |
| SCHEMBL641299 | 0.90 | ADORA3 (0.81) | ADORA3ADORA2AADORA1TSHRNFKB1 | |
| SCHEMBL638141 | 0.90 | PAX8 (1.00) | ADORA3ADORA2AADORA1TSHRNFKB1 | |
| SCHEMBL20626411 | 0.90 | PAX8 (1.00) | ADORA3ADORA2AADORA1TSHRNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 384 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024243-A1 | Fine Dry Particulate Adenosine Compositions and Topical Formulations Including the Same | LABORATORY SKIN CARE, INC. | 2024-01-25 | — | — | US | claimed |
| EP-2204154-B1 | Association of monosaccharides and adenosine and its cosmetic use | ORÉAL L (FR) | 2016-10-12 | — | — | EP | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| CN-101856313-B | Association of monosaccharides and adenosine and its cosmetic use | OREAL | 2014-02-19 | — | — | CN | claimed |
| US-20110262442-A1 | COMPOSITIONS FOR TREATING CNS DISORDERS | ADENIOS, INC. (US) | 2011-10-27 | — | — | US | claimed |
| WO-2011057199-A1 | COMPOSITIONS FOR TREATING CNS DISORDERS | ADENIOS, INC. (US) | 2011-05-12 | — | — | WO | claimed |
| CN-101856313-A | Association of monosaccharides and adenosine and its cosmetic use | OREAL | 2010-10-13 | — | — | CN | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| EP-2204154-A1 | Association of monosaccharides and adenosine and its cosmetic use | L'OREAL (FR) | 2010-07-07 | — | — | EP | claimed |
| US-20100168049-A1 | COMBINATION OF MONOSACCHARIDES AND ADENOSINE AND USE THEREOF | L'OREAL (FR) | 2010-07-01 | — | — | US | claimed |
| US-20040146474-A1 | Method for softening lines and relaxing the skin with adenosine and adenosine analogues | L'OREAL (FR) | 2004-07-29 | — | — | US | claimed |
| WO-2004058791-A2 | SUBSTITUTION DERIVATIVES OF N6-BENZYLADENOSINE, METHODS OF THEIR PREPARATION, THEIR USE FOR PREPARATION OF DRUGS, COSMETIC PREPARATIONS AND GROWTH REGULATORS, PHARMACEUTICAL PREPARATIONS, COSMETIC PREPARATIONS AND GROWTH REGULATORS CONTAINING THESE COMPOUNDS | USTAV EXPERIMENTALNI BOTANIKY AKADEMIE VED CESKE REPUBLIKY (CZ) | 2004-07-15 | — | — | WO | claimed |
| US-20040110718-A1 | Anti-HCV nucleoside derivatives | DEVOS RENE (GB) | 2004-06-10 | — | — | US | claimed |
| EP-1424064-A1 | Use of adenosin or an adenosin analog to smooth out fine lines | L'OREAL (FR) | 2004-06-02 | — | — | EP | claimed |
| CN-1466591-A | Nucleoside derivatives | - | 2004-01-07 | — | — | CN | claimed |
| WO-2002018404-A9 | NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | HOFFMANN LA ROCHE (CH) | 2003-10-02 | — | — | WO | claimed |
| EP-1315736-A2 | NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-04 | — | — | EP | claimed |
| WO-2002018404-A2 | NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | F. HOFFMANN-LA ROCHE AG (CH) | 2002-03-07 | — | — | WO | claimed |
| EP-0603348-A1 | PURINE DERIVATIVES | NOVO NORDISK A/S (DK) | 1994-06-29 | — | — | EP | claimed |
| WO-1993023418-A1 | PURINE DERIVATIVES | NOVO NORDISK A/S (DK) | 1993-11-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110718-A1 | Anti-HCV nucleoside derivatives | PNP, HAVCR2, NUDT14 | ADORA3 102/4885ADORA2A 70/4885ADORA1 197/4885 |
| US-20100168049-A1 | COMBINATION OF MONOSACCHARIDES AND ADENOSINE AND USE THEREOF | ADORA2A, ADORA1, ADORA3 | ADORA3 3/4885ADORA2A 1/4885ADORA1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.